CStone Pharmaceuticals 

CStone Pharmaceuticals is a biopharmaceutical firm dedicated to discovering, developing, and marketing innovative immuno-oncology and precision medicine therapies. Their primary objective is to fulfill critical medical requirements for cancer patients, both within China and across global markets. The company currently provides several key therapeutic agents. These include Sugemalimab, a monoclonal antibody specifically targeting programmed death-ligand 1 (PD-L1); GAVRETO, an RET inhibitor prescribed for advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor used in adults with unresectable or metastatic gastrointestinal stromal tumors that carry a PDGFRA exon 18 mutation. CStone's robust product pipeline features promising candidates such as Nofazinlimab, a PD-1 antibody aimed at treating hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor developed for adults experiencing relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor also indicated for hepatocellular carcinoma. Further augmenting its development portfolio are various compounds including CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500, all targeting solid tumors, alongside CS5001, which addresses both solid tumors and hematologic malignancies. Established in 2015, CStone Pharmaceuticals maintains its headquarters in Shanghai, China.